Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system.
It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2.
The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology.
The company was incorporated in 2003 and is headquartered in La Jolla, California.
As of March 7, 2024, Ambrx Biopharma Inc. operates as a subsidiary of Johnson & Johnson.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 23, 24 | 0.00 Increased by +100.00% | -0.05 Increased by +100.00% |
| Nov 16, 23 | -0.37 Decreased by N/A% | -0.19 Decreased by -94.74% |
| Aug 9, 23 | -0.35 Increased by +73.68% | -0.09 Decreased by -288.89% |
| May 11, 23 | -0.05 Increased by +44.44% | -0.05 |
| Mar 30, 23 | -0.10 Decreased by -42.86% | -0.13 Increased by +23.08% |
| Nov 30, 22 | 0.00 Increased by +100.00% | -0.11 Increased by +100.00% |
| Aug 29, 22 | -1.33 Increased by +76.75% | -0.09 Decreased by -1.38 K% |
| Apr 26, 22 | -0.09 Increased by +35.62% | -0.09 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 53.00 K Decreased by -97.64% | -22.99 M Decreased by -73.46% | Decreased by -43.38 K% Decreased by -7.25 K% |
| Jun 30, 23 | 1.12 M Decreased by -13.55% | -17.83 M Increased by +38.19% | Decreased by -1.59 K% Increased by +28.51% |
| Mar 31, 23 | 24.00 K Decreased by -97.93% | -15.30 M Increased by +27.80% | Decreased by -63.76 K% Decreased by -3.39 K% |
| Dec 31, 22 | 2.25 M Increased by +93.28% | -13.25 M Increased by +37.47% | Decreased by -590.36% Increased by +67.65% |
| Sep 30, 22 | 2.25 M Increased by +93.28% | -13.25 M Increased by +32.15% | Decreased by -590.36% Increased by +64.90% |
| Jun 30, 22 | 1.30 M Decreased by -49.38% | -28.84 M Decreased by -98.84% | Decreased by -2.22 K% Decreased by -292.79% |
| Mar 31, 22 | 1.16 M Decreased by -54.73% | -21.19 M Decreased by -46.12% | Decreased by -1.82 K% Decreased by -222.80% |
| Dec 31, 21 | 1.16 M Decreased by -67.70% | -21.19 M Decreased by -281.60% | Decreased by -1.82 K% Decreased by -1.08 K% |